Similar articles

• Ifosfamide with mesna uroprotection in the management of lung cancer.

  Holoye PY, Glisson BS, Lee JS, Dhingra HM, Murphy WK, Umsawasdi T, Levy JK, Jeffries D, Raber MN, Hong WK. Holoye PY, et al. Am J Clin Oncol. 1990 Apr;13(2):148-55. doi: 10.1097/00000421-199004000-00012. Am J Clin Oncol. 1990. PMID: 2156418
• Nursing implications in the administration of ifosfamide and mesna.

  Richters JE. Richters JE. Oncol Nurs Forum. 1990 Mar-Apr;17(2):276. Oncol Nurs Forum. 1990. PMID: 2107534 No abstract available.
• [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].

  Burkert H, Schnitker J, Fichtner E. Burkert H, et al. MMW Munch Med Wochenschr. 1979 Jun 1;121(22):760-2. MMW Munch Med Wochenschr. 1979. PMID: 112422 German.
• Ifosfamide and mesna.

  Schoenike SE, Dana WJ. Schoenike SE, et al. Clin Pharm. 1990 Mar;9(3):179-91. Clin Pharm. 1990. PMID: 2107997 Review.
• Ifosfamide and mesna in epithelial ovarian carcinoma.

  Sutton G. Sutton G. Gynecol Oncol. 1993 Oct;51(1):104-8. doi: 10.1006/gyno.1993.1254. Gynecol Oncol. 1993. PMID: 8244163 Review.